Insider transactions

EDGAR

RAPT Therapeutics, Inc.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-20.

Open-market purchases (code P)
0 transactions, — shares
Open-market sales (code S)
0 transactions, — shares

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–50 of 82

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-03-03 Filed 2026-03-05Kozick Linda Director
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
Disposed (D)4,956——0Direct (D) No
F1, F2, F3, F4
  • F1 Represents the annual grant of restricted stock units (RSUs) under the Issuer's Amended amp; Restated Non-Employee Director Compensation Policy, previously granted to the Reporting Person and reported on Form 4 dated February 2, 2026, which were scheduled to fully vest on the first anniversary of the grant date. Each RSU represents a contingent right to receive one share of common stock upon vesting.
  • F2 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
  • F3 Pursuant to the Merger Agreement, each RSU award that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash in an amount equal to (i) the total number of Shares issuable in settlement of such RSU immediately prior to the Effective Time without regard to vesting, multiplied by (ii) the Offer Price, which amount shall be paid in accordance with the Merger Agreement.
  • F4 This Form 4 reports securities transacted pursuant to the Merger Agreement.
Open filing 0001782274-26-000003 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Kozick Linda Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Director Stock Option (right to buy) — underlying Common Stock (2,083) — exercise price 16.32
Disposed (D)2,083——0Direct (D) No
F5, F2, F4, F6
  • F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
  • F2 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
  • F4 This Form 4 reports securities transacted pursuant to the Merger Agreement.
  • F6 Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration.
Open filing 0001782274-26-000003 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Kozick Linda Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Director Stock Option (right to buy) — underlying Common Stock (521) — exercise price 49.44
Disposed (D)521——0Direct (D) No
F5, F2, F4, F6
  • F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
  • F2 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
  • F4 This Form 4 reports securities transacted pursuant to the Merger Agreement.
  • F6 Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration.
Open filing 0001782274-26-000003 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Kozick Linda Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Director Stock Option (right to buy) — underlying Common Stock (521) — exercise price 108.96
Disposed (D)521——0Direct (D) No
F5, F2, F4, F6
  • F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
  • F2 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
  • F4 This Form 4 reports securities transacted pursuant to the Merger Agreement.
  • F6 Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration.
Open filing 0001782274-26-000003 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Kozick Linda Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Director Stock Option (right to buy) — underlying Common Stock (1,917) — exercise price 96
Disposed (D)1,917——0Direct (D) No
F5, F2, F4, F6
  • F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
  • F2 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
  • F4 This Form 4 reports securities transacted pursuant to the Merger Agreement.
  • F6 Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration.
Open filing 0001782274-26-000003 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Kozick Linda Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Director Stock Option (right to buy) — underlying Common Stock (417) — exercise price 96
Disposed (D)417——0Direct (D) No
F5, F2, F4, F6
  • F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
  • F2 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
  • F4 This Form 4 reports securities transacted pursuant to the Merger Agreement.
  • F6 Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration.
Open filing 0001782274-26-000003 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Kozick Linda Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Director Stock Option (right to buy) — underlying Common Stock (938) — exercise price 226.16
Disposed (D)938——0Direct (D) No
F5, F2, F4, F6
  • F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
  • F2 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
  • F4 This Form 4 reports securities transacted pursuant to the Merger Agreement.
  • F6 Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration.
Open filing 0001782274-26-000003 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Kozick Linda Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Director Stock Option (right to buy) — underlying Common Stock (938) — exercise price 154.40
Disposed (D)938——0Direct (D) No
F5, F2, F4, F6
  • F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
  • F2 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
  • F4 This Form 4 reports securities transacted pursuant to the Merger Agreement.
  • F6 Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration.
Open filing 0001782274-26-000003 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Kozick Linda Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Director Stock Option (right to buy) — underlying Common Stock (1,063) — exercise price 109.12
Disposed (D)1,063——0Direct (D) No
F5, F2, F4, F6
  • F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
  • F2 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
  • F4 This Form 4 reports securities transacted pursuant to the Merger Agreement.
  • F6 Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration.
Open filing 0001782274-26-000003 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Kozick Linda Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Director Stock Option (right to buy) — underlying Common Stock (1,618) — exercise price 167.44
Disposed (D)1,618——0Direct (D) No
F5, F2, F4, F6
  • F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
  • F2 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
  • F4 This Form 4 reports securities transacted pursuant to the Merger Agreement.
  • F6 Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration.
Open filing 0001782274-26-000003 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Kozick Linda Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Director Stock Option (right to buy) — underlying Common Stock (4,561) — exercise price 37.04
Disposed (D)4,561——0Direct (D) No
F5, F2, F4, F6
  • F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
  • F2 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
  • F4 This Form 4 reports securities transacted pursuant to the Merger Agreement.
  • F6 Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration.
Open filing 0001782274-26-000003 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Kozick Linda Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Director Stock Option (right to buy) — underlying Common Stock (32,229) — exercise price 7.44
Disposed (D)32,229——0Direct (D) No
F5, F2, F4, F6
  • F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
  • F2 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
  • F4 This Form 4 reports securities transacted pursuant to the Merger Agreement.
  • F6 Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration.
Open filing 0001782274-26-000003 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Wong Brian Russell Director · Officer: PRESIDENT AND CEO
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
Disposed (D)64,102——0Direct (D) No
F1, F2, F3, F4
  • F1 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
  • F2 This Form 4 reports securities transacted pursuant to the Merger Agreement.
  • F3 The number of shares was adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
  • F4 Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of common stock held by the Reporting Person was tendered in exchange for the Offer Price.
Open filing 0001646110-26-000001 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Wong Brian Russell Director · Officer: PRESIDENT AND CEO
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (25,000) — exercise price 49.44
Disposed (D)25,000——0Direct (D) No
F5, F1, F2, F6
  • F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
  • F1 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
  • F2 This Form 4 reports securities transacted pursuant to the Merger Agreement.
  • F6 Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was less than Offer Price was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option.
Open filing 0001646110-26-000001 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Wong Brian Russell Director · Officer: PRESIDENT AND CEO
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (8,334) — exercise price 50.40
Disposed (D)8,334——0Direct (D) No
F5, F1, F2, F6
  • F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
  • F1 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
  • F2 This Form 4 reports securities transacted pursuant to the Merger Agreement.
  • F6 Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was less than Offer Price was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option.
Open filing 0001646110-26-000001 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Wong Brian Russell Director · Officer: PRESIDENT AND CEO
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (10,417) — exercise price 12.56
Disposed (D)10,417——0Direct (D) No
F5, F1, F2, F6
  • F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
  • F1 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
  • F2 This Form 4 reports securities transacted pursuant to the Merger Agreement.
  • F6 Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was less than Offer Price was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option.
Open filing 0001646110-26-000001 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Wong Brian Russell Director · Officer: PRESIDENT AND CEO
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (7,500) — exercise price 12.56
Disposed (D)7,500——0Direct (D) No
F5, F1, F2, F6
  • F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
  • F1 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
  • F2 This Form 4 reports securities transacted pursuant to the Merger Agreement.
  • F6 Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was less than Offer Price was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option.
Open filing 0001646110-26-000001 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Wong Brian Russell Director · Officer: PRESIDENT AND CEO
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (18,750) — exercise price 12.56
Disposed (D)18,750——0Direct (D) No
F5, F1, F2, F6
  • F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
  • F1 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
  • F2 This Form 4 reports securities transacted pursuant to the Merger Agreement.
  • F6 Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was less than Offer Price was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option.
Open filing 0001646110-26-000001 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Wong Brian Russell Director · Officer: PRESIDENT AND CEO
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (37,500) — exercise price 12.56
Disposed (D)37,500——0Direct (D) No
F5, F1, F2, F6
  • F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
  • F1 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
  • F2 This Form 4 reports securities transacted pursuant to the Merger Agreement.
  • F6 Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was less than Offer Price was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option.
Open filing 0001646110-26-000001 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Wong Brian Russell Director · Officer: PRESIDENT AND CEO
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (31,250) — exercise price 12.56
Disposed (D)31,250——0Direct (D) No
F5, F1, F2, F6
  • F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
  • F1 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
  • F2 This Form 4 reports securities transacted pursuant to the Merger Agreement.
  • F6 Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was less than Offer Price was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option.
Open filing 0001646110-26-000001 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Wong Brian Russell Director · Officer: PRESIDENT AND CEO
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (34,375) — exercise price 12.56
Disposed (D)34,375——0Direct (D) No
F5, F1, F2, F6
  • F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
  • F1 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
  • F2 This Form 4 reports securities transacted pursuant to the Merger Agreement.
  • F6 Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was less than Offer Price was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option.
Open filing 0001646110-26-000001 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Wong Brian Russell Director · Officer: PRESIDENT AND CEO
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (218,250) — exercise price 9.12
Disposed (D)218,250——0Direct (D) No
F5, F1, F2, F6
  • F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
  • F1 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
  • F2 This Form 4 reports securities transacted pursuant to the Merger Agreement.
  • F6 Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was less than Offer Price was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option.
Open filing 0001646110-26-000001 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Wong Brian Russell Director · Officer: PRESIDENT AND CEO
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (371,875) — exercise price 7.43
Disposed (D)371,875——265,625Direct (D) No
F1, F2, F7, F8
  • F1 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
  • F2 This Form 4 reports securities transacted pursuant to the Merger Agreement.
  • F7 Pursuant to the terms of the Merger Agreement, each stock option that is unvested as of immediately prior to the Effective Time and was granted after March 1, 2025 (a 2025 Option) was cancelled and converted into a cash-based award of Parent (a Converted Option), which shall entitle the holder thereof to receive an amount in cash equal to the Option Consideration (the Converted Option Consideration).
  • F8 Each Converted Option (and the right to receive the Converted Option Consideration) shall be subject to the same terms and conditions (including vesting, forfeiture and acceleration provisions) that were applicable to the corresponding 2025 Option immediately prior to the Effective Time; provided, that (i) the Converted Option Consideration shall vest and become payable 50% upon the date that closing occurs pursuant to the Merger Agreement (the Closing Date) and 50% upon the date that is nine months following the Closing Date and (ii) in the event that the holder of a Converted Option experiences an Involuntary Termination (as defined in the Merger Agreement) following the Closing Date but prior to the date that is nine months following the Closing Date, such holder's Converted Option Consideration shall immediately vest and become payable without any further action on the part of Parent or any other person.
Open filing 0001646110-26-000001 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Lyons-Williams Lori Director
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
Disposed (D)4,956——0Direct (D) No
F1, F2, F3, F4
  • F1 Represents the annual grant of restricted stock units (RSUs) under the Issuer's Amended amp; Restated Non-Employee Director Compensation Policy, previously granted to the Reporting Person and reported on Form 4 dated February 2, 2026, which were scheduled to fully vest on the first anniversary of the grant date. Each RSU represents a contingent right to receive one share of common stock upon vesting.
  • F2 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
  • F3 Pursuant to the Merger Agreement, each RSU award that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash in an amount equal to (i) the total number of Shares issuable in settlement of such RSU immediately prior to the Effective Time without regard to vesting, multiplied by (ii) the Offer Price, which amount shall be paid in accordance with the Merger Agreement.
  • F4 This Form 4 reports securities transacted pursuant to the Merger Agreement.
Open filing 0001693564-26-000003 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Lyons-Williams Lori Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Director Stock Option (right to buy) — underlying Common Stock (2,813) — exercise price 306.24
Disposed (D)2,813——0Direct (D) No
F5, F2, F4, F6
  • F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
  • F2 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
  • F4 This Form 4 reports securities transacted pursuant to the Merger Agreement.
  • F6 Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration.
Open filing 0001693564-26-000003 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Lyons-Williams Lori Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Director Stock Option (right to buy) — underlying Common Stock (1,063) — exercise price 109.12
Disposed (D)1,063——0Direct (D) No
F5, F2, F4, F6
  • F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
  • F2 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
  • F4 This Form 4 reports securities transacted pursuant to the Merger Agreement.
  • F6 Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration.
Open filing 0001693564-26-000003 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Lyons-Williams Lori Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Director Stock Option (right to buy) — underlying Common Stock (1,618) — exercise price 167.44
Disposed (D)1,618——0Direct (D) No
F5, F2, F4, F6
  • F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
  • F2 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
  • F4 This Form 4 reports securities transacted pursuant to the Merger Agreement.
  • F6 Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration.
Open filing 0001693564-26-000003 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Lyons-Williams Lori Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Director Stock Option (right to buy) — underlying Common Stock (4,561) — exercise price 37.04
Disposed (D)4,561——0Direct (D) No
F5, F2, F4, F6
  • F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
  • F2 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
  • F4 This Form 4 reports securities transacted pursuant to the Merger Agreement.
  • F6 Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration.
Open filing 0001693564-26-000003 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Lyons-Williams Lori Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Director Stock Option (right to buy) — underlying Common Stock (32,229) — exercise price 7.44
Disposed (D)32,229——0Direct (D) No
F5, F2, F4, F6
  • F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
  • F2 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
  • F4 This Form 4 reports securities transacted pursuant to the Merger Agreement.
  • F6 Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration.
Open filing 0001693564-26-000003 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Brockstedt Dirk G. Officer: CHIEF SCIENTIFIC OFFICER
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
Disposed (D)4,648——0Direct (D) No
F1, F2, F3, F4
  • F1 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
  • F2 This Form 4 reports securities transacted pursuant to the Merger Agreement.
  • F3 The number of shares was adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
  • F4 Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of common stock held by the Reporting Person was tendered in exchange for the Offer Price.
Open filing 0001635616-26-000001 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Brockstedt Dirk G. Officer: CHIEF SCIENTIFIC OFFICER
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (1,225) — exercise price 49.44
Disposed (D)1,225——0Direct (D) No
F5, F1, F2, F6
  • F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
  • F1 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
  • F2 This Form 4 reports securities transacted pursuant to the Merger Agreement.
  • F6 Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration.
Open filing 0001635616-26-000001 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Brockstedt Dirk G. Officer: CHIEF SCIENTIFIC OFFICER
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (1,035) — exercise price 50.40
Disposed (D)1,035——0Direct (D) No
F5, F1, F2, F6
  • F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
  • F1 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
  • F2 This Form 4 reports securities transacted pursuant to the Merger Agreement.
  • F6 Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration.
Open filing 0001635616-26-000001 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Brockstedt Dirk G. Officer: CHIEF SCIENTIFIC OFFICER
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (3,125) — exercise price 108.96
Disposed (D)3,125——0Direct (D) No
F5, F1, F2, F6
  • F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
  • F1 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
  • F2 This Form 4 reports securities transacted pursuant to the Merger Agreement.
  • F6 Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration.
Open filing 0001635616-26-000001 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Brockstedt Dirk G. Officer: CHIEF SCIENTIFIC OFFICER
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (2,500) — exercise price 12.56
Disposed (D)2,500——0Direct (D) No
F5, F1, F2, F6
  • F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
  • F1 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
  • F2 This Form 4 reports securities transacted pursuant to the Merger Agreement.
  • F6 Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration.
Open filing 0001635616-26-000001 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Brockstedt Dirk G. Officer: CHIEF SCIENTIFIC OFFICER
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (6,250) — exercise price 12.56
Disposed (D)6,250——0Direct (D) No
F5, F1, F2, F6
  • F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
  • F1 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
  • F2 This Form 4 reports securities transacted pursuant to the Merger Agreement.
  • F6 Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration.
Open filing 0001635616-26-000001 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Brockstedt Dirk G. Officer: CHIEF SCIENTIFIC OFFICER
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (3,876) — exercise price 12.56
Disposed (D)6,876——0Direct (D) No
F5, F1, F2, F6
  • F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
  • F1 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
  • F2 This Form 4 reports securities transacted pursuant to the Merger Agreement.
  • F6 Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration.
Open filing 0001635616-26-000001 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Brockstedt Dirk G. Officer: CHIEF SCIENTIFIC OFFICER
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (7,000) — exercise price 12.56
Disposed (D)7,000——0Direct (D) No
F5, F1, F2, F6
  • F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
  • F1 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
  • F2 This Form 4 reports securities transacted pursuant to the Merger Agreement.
  • F6 Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration.
Open filing 0001635616-26-000001 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Brockstedt Dirk G. Officer: CHIEF SCIENTIFIC OFFICER
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (9,375) — exercise price 12.56
Disposed (D)9,375——0Direct (D) No
F5, F1, F2, F6
  • F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
  • F1 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
  • F2 This Form 4 reports securities transacted pursuant to the Merger Agreement.
  • F6 Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration.
Open filing 0001635616-26-000001 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Brockstedt Dirk G. Officer: CHIEF SCIENTIFIC OFFICER
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (64,375) — exercise price 9.12
Disposed (D)64,375——0Direct (D) No
F5, F1, F2, F6
  • F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
  • F1 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
  • F2 This Form 4 reports securities transacted pursuant to the Merger Agreement.
  • F6 Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration.
Open filing 0001635616-26-000001 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Brockstedt Dirk G. Officer: CHIEF SCIENTIFIC OFFICER
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (58,333) — exercise price 7.43
Disposed (D)58,333——41,667Direct (D) No
F1, F2, F7, F8
  • F1 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
  • F2 This Form 4 reports securities transacted pursuant to the Merger Agreement.
  • F7 Pursuant to the terms of the Merger Agreement, each stock option that is unvested as of immediately prior to the Effective Time and was granted after March 1, 2025 (a 2025 Option) was cancelled and converted into a cash-based award of Parent (a Converted Option), which shall entitle the holder thereof to receive an amount in cash equal to the Option Consideration (the Converted Option Consideration).
  • F8 Each Converted Option (and the right to receive the Converted Option Consideration) shall be subject to the same terms and conditions (including vesting, forfeiture and acceleration provisions) that were applicable to the corresponding 2025 Option immediately prior to the Effective Time; provided, that (i) the Converted Option Consideration shall vest and become payable 50% upon the date that closing occurs pursuant to the Merger Agreement (the Closing Date) and 50% upon the date that is nine months following the Closing Date and (ii) in the event that the holder of a Converted Option experiences an Involuntary Termination (as defined in the Merger Agreement) following the Closing Date but prior to the date that is nine months following the Closing Date, such holder's Converted Option Consideration shall immediately vest and become payable without any further action on the part of Parent or any other person.
Open filing 0001635616-26-000001 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Young Rodney KB Officer: CHIEF FINANCIAL OFFICER
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
Disposed (D)3,304——0Direct (D) No
F1, F2, F3, F4
  • F1 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
  • F2 This Form 4 reports securities transacted pursuant to the Merger Agreement.
  • F3 The number of shares was adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
  • F4 Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of common stock held by the Reporting Person was tendered in exchange for the Offer Price.
Open filing 0001337831-26-000001 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Young Rodney KB Officer: CHIEF FINANCIAL OFFICER
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (17,501) — exercise price 12.56
Disposed (D)17,501——0Direct (D) No
F5, F1, F2, F6
  • F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
  • F1 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
  • F2 This Form 4 reports securities transacted pursuant to the Merger Agreement.
  • F6 Pursuant to the terms of the Merger Agreement, each stock option Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was less than Offer Price was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option.
Open filing 0001337831-26-000001 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Young Rodney KB Officer: CHIEF FINANCIAL OFFICER
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (7,500) — exercise price 12.56
Disposed (D)7,500——0Direct (D) No
F5, F1, F2, F6
  • F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
  • F1 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
  • F2 This Form 4 reports securities transacted pursuant to the Merger Agreement.
  • F6 Pursuant to the terms of the Merger Agreement, each stock option Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was less than Offer Price was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option.
Open filing 0001337831-26-000001 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Young Rodney KB Officer: CHIEF FINANCIAL OFFICER
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (8,125) — exercise price 12.56
Disposed (D)8,125——0Direct (D) No
F5, F1, F2, F6
  • F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
  • F1 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
  • F2 This Form 4 reports securities transacted pursuant to the Merger Agreement.
  • F6 Pursuant to the terms of the Merger Agreement, each stock option Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was less than Offer Price was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option.
Open filing 0001337831-26-000001 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Young Rodney KB Officer: CHIEF FINANCIAL OFFICER
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (8,501) — exercise price 12.56
Disposed (D)8,501——0Direct (D) No
F5, F1, F2, F6
  • F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
  • F1 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
  • F2 This Form 4 reports securities transacted pursuant to the Merger Agreement.
  • F6 Pursuant to the terms of the Merger Agreement, each stock option Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was less than Offer Price was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option.
Open filing 0001337831-26-000001 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Young Rodney KB Officer: CHIEF FINANCIAL OFFICER
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (11,251) — exercise price 12.56
Disposed (D)11,251——0Direct (D) No
F5, F1, F2, F6
  • F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
  • F1 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
  • F2 This Form 4 reports securities transacted pursuant to the Merger Agreement.
  • F6 Pursuant to the terms of the Merger Agreement, each stock option Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was less than Offer Price was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option.
Open filing 0001337831-26-000001 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Young Rodney KB Officer: CHIEF FINANCIAL OFFICER
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (80,250) — exercise price 9.12
Disposed (D)80,250——0Direct (D) No
F5, F1, F2, F6
  • F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
  • F1 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
  • F2 This Form 4 reports securities transacted pursuant to the Merger Agreement.
  • F6 Pursuant to the terms of the Merger Agreement, each stock option Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was less than Offer Price was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option.
Open filing 0001337831-26-000001 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Young Rodney KB Officer: CHIEF FINANCIAL OFFICER
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (69,271) — exercise price 7.43
Disposed (D)69,271——49,479Direct (D) No
F1, F2, F7, F8
  • F1 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
  • F2 This Form 4 reports securities transacted pursuant to the Merger Agreement.
  • F7 Pursuant to the terms of the Merger Agreement, each stock option that is unvested as of immediately prior to the Effective Time and was granted after March 1, 2025 (a 2025 Option) was cancelled and converted into a cash-based award of Parent (a Converted Option), which shall entitle the holder thereof to receive an amount in cash equal to the Option Consideration (the Converted Option Consideration).
  • F8 Each Converted Option (and the right to receive the Converted Option Consideration) shall be subject to the same terms and conditions (including vesting, forfeiture and acceleration provisions) that were applicable to the corresponding 2025 Option immediately prior to the Effective Time; provided, that (i) the Converted Option Consideration shall vest and become payable 50% upon the date that closing occurs pursuant to the Merger Agreement (the Closing Date) and 50% upon the date that is nine months following the Closing Date and (ii) in the event that the holder of a Converted Option experiences an Involuntary Termination (as defined in the Merger Agreement) following the Closing Date but prior to the date that is nine months following the Closing Date, such holder's Converted Option Consideration shall immediately vest and become payable without any further action on the part of Parent or any other person.
Open filing 0001337831-26-000001 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Braunstein Scott Director
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
Disposed (D)4,956——0Direct (D) No
F1, F2, F3, F4
  • F1 Represents the annual grant of restricted stock units (RSUs) under the Issuer's Amended amp; Restated Non-Employee Director Compensation Policy, previously granted to the Reporting Person and reported on Form 4 dated February 2, 2026, which were scheduled to fully vest on the first anniversary of the grant date. Each RSU represents a contingent right to receive one share of common stock upon vesting.
  • F2 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
  • F3 Pursuant to the Merger Agreement, each RSU award that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash in an amount equal to (i) the total number of Shares issuable in settlement of such RSU immediately prior to the Effective Time without regard to vesting, multiplied by (ii) the Offer Price, which amount shall be paid in accordance with the Merger Agreement.
  • F4 This Form 4 reports securities transacted pursuant to the Merger Agreement.
Open filing 0001643875-26-000006 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Braunstein Scott Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Director Stock Option (right to buy) — underlying Common Stock (25,000) — exercise price 7.44
Disposed (D)25,000——0Direct (D) No
F2, F4, F5
  • F2 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
  • F4 This Form 4 reports securities transacted pursuant to the Merger Agreement.
  • F5 Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was less than Offer Price was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option.
Open filing 0001643875-26-000006 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

No Form 13F position in this issuer is placed in the store. A holder not yet linked or not yet filed is absent, not zero.

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
RTW Investments, LP Common Stock, $0.0001 par value0.00.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 2Open filing 0001493215-26-000114 Dispute this row
Roderick Wong Common Stock, $0.0001 par value0.00.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 2Open filing 0001493215-26-000114 Dispute this row
ORBIMED ADVISORS LLC Common Stock, par value $0.0001 per share00.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 2Open filing 0000947871-26-000551 Dispute this row
Glazer Capital, LLC Common Stock $0.0001 par value per share5.361,486,094.0002/02/2026 Filed 2026-02-09SCHEDULE 13GOpen filing 0001076809-26-000009 Dispute this row
Paul J. Glazer Common Stock $0.0001 par value per share5.361,486,094.0002/02/2026 Filed 2026-02-09SCHEDULE 13GOpen filing 0001076809-26-000009 Dispute this row
RTW Investments, LP Common Stock, $0.0001 par value5.91,637,165.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 1Open filing 0001493215-26-000046 Dispute this row
Roderick Wong Common Stock, $0.0001 par value5.91,637,165.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 1Open filing 0001493215-26-000046 Dispute this row
Deep Track Capital, LP Common Stock $0.0001 par value per share0.40110,448.0012/31/2025 Filed 2026-02-13SCHEDULE 13G/AAmendment 1Open filing 0001172661-26-000721 Dispute this row
Deep Track Biotechnology Master Fund, Ltd. Common Stock $0.0001 par value per share0.40110,448.0012/31/2025 Filed 2026-02-13SCHEDULE 13G/AAmendment 1Open filing 0001172661-26-000721 Dispute this row
David Kroin Common Stock $0.0001 par value per share0.40110,448.0012/31/2025 Filed 2026-02-13SCHEDULE 13G/AAmendment 1Open filing 0001172661-26-000721 Dispute this row
ForGrowth III PA B.V. Common Stock $0.0001 par value per share7.41,833,33310/23/2025 Filed 2025-10-29SCHEDULE 13GOpen filing 0001193125-25-256980 Dispute this row
Forbion Growth Opportunities Fund III Cooperatief U.A. Common Stock $0.0001 par value per share7.41,833,33310/23/2025 Filed 2025-10-29SCHEDULE 13GOpen filing 0001193125-25-256980 Dispute this row
Forbion Growth III Management B.V. Common Stock $0.0001 par value per share7.41,833,33310/23/2025 Filed 2025-10-29SCHEDULE 13GOpen filing 0001193125-25-256980 Dispute this row
ORBIMED ADVISORS LLC Common Stock, par value $0.0001 per share6.61,086,618.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 1Open filing 0000947871-25-001022 Dispute this row
Nantahala Capital Management, LLC Common Stock $0.0001 par value per share3.77623,282.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 1Open filing 0001104659-25-112626 Dispute this row
Wilmot B. Harkey Common Stock $0.0001 par value per share3.77623,282.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 1Open filing 0001104659-25-112626 Dispute this row
Daniel Mack Common Stock $0.0001 par value per share3.77623,282.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 1Open filing 0001104659-25-112626 Dispute this row
BIOTECHNOLOGY VALUE FUND L P Common Stock, $0.0001 par value per share00.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 1Open filing 0000921895-25-003115 Dispute this row
BVF I GP LLC Common Stock, $0.0001 par value per share00.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 1Open filing 0000921895-25-003115 Dispute this row
BIOTECHNOLOGY VALUE FUND II LP Common Stock, $0.0001 par value per share00.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 1Open filing 0000921895-25-003115 Dispute this row
BVF II GP LLC Common Stock, $0.0001 par value per share00.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 1Open filing 0000921895-25-003115 Dispute this row
Biotechnology Value Trading Fund OS LP Common Stock, $0.0001 par value per share00.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 1Open filing 0000921895-25-003115 Dispute this row
BVF Partners OS Ltd. Common Stock, $0.0001 par value per share00.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 1Open filing 0000921895-25-003115 Dispute this row
BVF GP HOLDINGS LLC Common Stock, $0.0001 par value per share00.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 1Open filing 0000921895-25-003115 Dispute this row
BVF PARTNERS L P/IL Common Stock, $0.0001 par value per share00.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 1Open filing 0000921895-25-003115 Dispute this row
BVF INC/IL Common Stock, $0.0001 par value per share00.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 1Open filing 0000921895-25-003115 Dispute this row
LAMPERT MARK N Common Stock, $0.0001 par value per share00.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 1Open filing 0000921895-25-003115 Dispute this row
The Vanguard Group Common Stock4.20696,18809/30/2025 Filed 2025-10-30SCHEDULE 13G/AAmendment 1Open filing 0000102909-25-000216 Dispute this row
Redmile Group, LLC Common Stock, $0.0001 par value per share9.91,765,303.0006/30/2025 Filed 2025-08-14SCHEDULE 13G/AAmendment 4Open filing 0001104659-25-078636 Dispute this row
Jeremy C. Green Common Stock, $0.0001 par value per share9.91,765,303.0006/30/2025 Filed 2025-08-14SCHEDULE 13G/AAmendment 4Open filing 0001104659-25-078636 Dispute this row
Redmile Biopharma Investments III, L.P. Common Stock, $0.0001 par value per share6.51,147,390.0006/30/2025 Filed 2025-08-14SCHEDULE 13G/AAmendment 4Open filing 0001104659-25-078636 Dispute this row
Nantahala Capital Management, LLC Common Stock $0.0001 par value per share5.75951,613.0006/30/2025 Filed 2025-08-14SCHEDULE 13GOpen filing 0001104659-25-078686 Dispute this row
Wilmot B. Harkey Common Stock $0.0001 par value per share5.75951,613.0006/30/2025 Filed 2025-08-14SCHEDULE 13GOpen filing 0001104659-25-078686 Dispute this row
Daniel Mack Common Stock $0.0001 par value per share5.75951,613.0006/30/2025 Filed 2025-08-14SCHEDULE 13GOpen filing 0001104659-25-078686 Dispute this row
Foresite Capital Fund VI, L.P. Common Stock9.312,500,000.0012/23/2024 Filed 2024-12-30SCHEDULE 13GOpen filing 0001104659-24-132464 Dispute this row
Foresite Capital Management VI, LLC Common Stock9.312,500,000.0012/23/2024 Filed 2024-12-30SCHEDULE 13GOpen filing 0001104659-24-132464 Dispute this row
James Tananbaum Common Stock9.312,500,000.0012/23/2024 Filed 2024-12-30SCHEDULE 13GOpen filing 0001104659-24-132464 Dispute this row
The Column Group II, LP Common Stock, $0.0001 par value0.6179,57912/23/2024 Filed 2024-12-23SCHEDULE 13D/AAmendment 7Open filing 0000950170-24-139851 Dispute this row
The Column Group II GP, LP Common Stock, $0.0001 par value0.6179,57912/23/2024 Filed 2024-12-23SCHEDULE 13D/AAmendment 7Open filing 0000950170-24-139851 Dispute this row
Ponoi Capital, LP Common Stock, $0.0001 par value0.4129,57912/23/2024 Filed 2024-12-23SCHEDULE 13D/AAmendment 7Open filing 0000950170-24-139851 Dispute this row
Ponoi Management, LLC Common Stock, $0.0001 par value0.4129,57912/23/2024 Filed 2024-12-23SCHEDULE 13D/AAmendment 7Open filing 0000950170-24-139851 Dispute this row
Ponoi Capital II, LP Common Stock, $0.0001 par value0.5145,40112/23/2024 Filed 2024-12-23SCHEDULE 13D/AAmendment 7Open filing 0000950170-24-139851 Dispute this row
Ponoi II Management, LLC Common Stock, $0.0001 par value0.5145,40112/23/2024 Filed 2024-12-23SCHEDULE 13D/AAmendment 7Open filing 0000950170-24-139851 Dispute this row
The Column Group IV, LP Common Stock, $0.0001 par value3.91,236,26112/23/2024 Filed 2024-12-23SCHEDULE 13D/AAmendment 7Open filing 0000950170-24-139851 Dispute this row
The Column Group IV-A, LP Common Stock, $0.0001 par value0.142,18912/23/2024 Filed 2024-12-23SCHEDULE 13D/AAmendment 7Open filing 0000950170-24-139851 Dispute this row
The Column Group IV GP, LP Common Stock, $0.0001 par value41,278,45012/23/2024 Filed 2024-12-23SCHEDULE 13D/AAmendment 7Open filing 0000950170-24-139851 Dispute this row
The Column Group, LLC Common Stock, $0.0001 par value016312/23/2024 Filed 2024-12-23SCHEDULE 13D/AAmendment 7Open filing 0000950170-24-139851 Dispute this row
Peter Svennilson Common Stock, $0.0001 par value4.91,603,59312/23/2024 Filed 2024-12-23SCHEDULE 13D/AAmendment 7Open filing 0000950170-24-139851 Dispute this row
David V. Goeddel Common Stock, $0.0001 par value4.91,603,59312/23/2024 Filed 2024-12-23SCHEDULE 13D/AAmendment 7Open filing 0000950170-24-139851 Dispute this row
Tim Kutzkey Common Stock, $0.0001 par value4.81,553,59312/23/2024 Filed 2024-12-23SCHEDULE 13D/AAmendment 7Open filing 0000950170-24-139851 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,584,041 filings read, dated 2004-06-14 to 2026-11-19: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
201517,857
2016222,642
2017222,009
2018223,345
2019216,482
2020210,332
2021249,835
2022231,682
2023229,674
2024234,045
2025235,520
2026262,405

Filings made before the SEC required XML are listed, not extracted.

Back to RAPT Therapeutics, Inc.